FEASIBILITY AND DOSIMETRIC EVALUATION OF CT-BASED HIGH DOSE-RATE INTERSTITIAL BRACHYTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER: A PROSPECTIVE STUDY
Main Article Content
Keywords
Interstitial brachytherapy,, Cervical cancer, CT-scan, GEC-ESTRO guidelines, Dose-volume histogram
Abstract
Purpose: This study evaluates the feasibility and efficacy of CT-based high dose-rate interstitial brachytherapy (HDR-ISBT) for the treatment of locally advanced uterine cervical cancer, following GEC-ESTRO guidelines. The primary objectives were to assess dosimetric outcomes, evaluate organ-at-risk (OAR) toxicity, and analyze local control and survival rates.
Methods and Materials: A cohort of 20 patients with biopsy-confirmed FIGO stage IIB-IIIB cervical cancer was treated using HDR-ISBT with the Syed-Neblett template, following external beam radiotherapy (EBRT) of 45 Gy in 25 fractions. Treatment planning was conducted with CT-based imaging, and dose-volume histograms (DVH) were generated for the high-risk clinical target volume (HR-CTV), intermediate-risk clinical target volume (IR-CTV), and OARs (bladder and rectum). The biologically equivalent dose in 2-Gy fractions (EQD2) was calculated for comparison.
Results: The median D90 for HR-CTV was 6.09 Gy per fraction (range: 3.57–6.81 Gy), and for IR-CTV, it was 4.35 Gy (range: 1.92–5.29 Gy). The median V100 for HR-CTV was 90.82% (range: 67–97%), and for IR-CTV, it was 54% (range: 40–73.9%). After adding the EBRT dose, the median EQD2 D90 for HR-CTV was 66.65 Gy, and the D100 was 53.45 Gy. The D2cc doses to the bladder and rectum were 66.5 Gy (range: 56.8–78.4 Gy) and 67.9 Gy (range: 61.7–73.9 Gy), respectively.
Conclusion: CT-based HDR-ISBT is a feasible and effective approach for treating locally advanced cervical cancer, providing adequate target volume coverage and minimizing OAR exposure. While CT is appropriate for OAR delineation, MRI remains the preferred modality for precise tumor volume contouring.
References
2. Kirisits C, Pötter R, Lang S, et al. Dose-volume histogram relationships in MRI-based cervical cancer brachytherapy: Impact on treatment outcomes. Radiother Oncol. 2009;93(2):311-317.
3. Dimopoulos JC, Schmid MP, Berger D, et al. The Vienna brachytherapy concept for locally advanced cervical cancer: Definitive results of image-guided adaptive brachytherapy combined with 3D conformal radiotherapy and MRI-based treatment planning. Strahlenther Onkol. 2010;186(2):82-90.
4. Viswanathan AN, Dimopoulos J, Kirisits C, et al. CT-based planning for interstitial brachytherapy in cervical cancer: Are CT-based methods effective alternatives to MRI-guided brachytherapy? Int J Radiat Oncol Biol Phys. 2008;72(1):153-159.
5. Rai B, Arora PK, Yadav V. CT-based HDR brachytherapy for locally advanced cervical cancer: Dosimetric analysis and clinical outcomes. Indian J Radiol Imaging. 2019;29(2):162-169.
6. Tanderup K, Viswanathan AN, Kirisits C, et al. Image-guided brachytherapy for cervical cancer: A comprehensive review of current evidence. Radiother Oncol. 2020;151:152-162.
7. Haie-Meder C, Pötter R, Van Limbergen E, et al. Recommendations from GYN GEC-ESTRO working group (II): Dose-volume parameters and DVH analysis in image-based brachytherapy. Radiother Oncol. 2005;74(3):231-245.
8. Pötter R, Georg P, Dimopoulos JC, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer: 10-year results from the EMBRACE-I study. Lancet Oncol. 2021;22(4):538-547.
9. Schmid MP, Kirisits C, Nesvacil N, et al. Long-term outcome of MRI-guided brachytherapy for cervical cancer: Local control and late toxicity in the prospective EMBRACE-I study. Brachytherapy. 2022;21(4):643-650.
10. Schmid MP, Fidarova EF, Pötter R, et al. Disease-free survival and local control after image-guided brachytherapy for cervical cancer. Strahlenther Onkol. 2019;195(11):933-942.
11. Trifiletti DM, Showalter TN, Grover S, et al. Evaluation of dual-energy CT for target delineation in cervical cancer radiotherapy: A prospective study. Radiother Oncol. 2018;129(2):173-180.
12. Kirisits C, Lang S, Dimopoulos JC, et al. Dose-volume histogram relationships in MRI-based cervical cancer brachytherapy: Impact on treatment outcomes. Radiother Oncol. 2009;93(2):311-317.
13. Fellner C, et al. Brachytherapy for cervical cancer: A review of current practice and outcomes. Cancer Treat Rev. 2013;39(5):475-482.
14. Pötter R, Schmid MP, Dimopoulos JC, et al. Local control and survival after MRI-guided brachytherapy for cervical cancer: 10-year results from the prospective EMBRACE-I study. Lancet Oncol. 2021;22(3).
15. Levendag PC, et al. Clinical relevance of contrast-enhanced CT in radiotherapy planning for cervical cancer. Clin Oncol. 2012;24(1):14-20.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr Aruna R.
Assistant professor Department of Radiation Oncology, Bangalore medical college and research institute Bangalore, India
Dr Thejaswini B
Professor &HOD Department of Radiation oncology Kidwai Memorial Institute of Oncology, Bangalore, India
Dr G V Giri
Professor Department of Radiation oncology Sri Shankara cancer hospital and research center Bangalore, India
Dr Aradhana Katke
Professor Department of Radiation oncology Kidwai Memorial Institute of Oncology,
Bangalore, India
Dr Nanda R
Professor Department of Radiation oncology Kidwai Memorial Institute of Oncology, Bangalore, India
Dr Shwetha
Associate professor Department of Medical Physics, Kidwai Memorial Institute of Oncology,
Bangalore, India